<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre=": Original Article Pharmacological inhibition of poly (ADP-ribose) polymerase by" exact="olaparib" post="ameliorates influenza-virus-induced pneumonia in mice LiuWeiliuwei19801116@163.com1RenXiaojuan2WangQian2ZhangYan2DuJunfeng3[1], grid.452270.60000 0004 0614"/>
 <result pre="This study aimed to explore the effects of PARP-1 inhibitor" exact="olaparib" post="on IAV-induced lung injury and the underlying mechanisms. Male"/>
 <result pre="intranasally infected with IAV strain H1N1 to mimic pneumonia experimentally." exact="Olaparib" post="at different doses was intraperitoneally injected 2Â days before"/>
 <result pre="lavage fluid (BALF) were sampled for histological and biochemical analyses." exact="Olaparib" post="increased the survival rate of IAV mice dose-dependently. Olaparib"/>
 <result pre="analyses. Olaparib increased the survival rate of IAV mice dose-dependently." exact="Olaparib" post="remarkably reduced IAV mRNA expression, myeloperoxidase (MPO) level, and"/>
 <result pre="(MPO) level, and inflammatory cell infiltration in IAV lungs. Moreover," exact="olaparib" post="significantly reduced the level of interleukin (IL)-1Î², tumor necrosis"/>
 <result pre="IL-6, and IL-4 and increased IL-10 in IAV lungs. Also," exact="olaparib" post="efficiently reduced IL-6, monocyte chemotactic protein (MCP)-1, granulocyte colony-stimulating"/>
 <result pre="T cell expressed and secreted (RANTES) release in IAV BALF." exact="Olaparib" post="decreased PARylated protein content and p65, IÎºBÎ± phosphorylation in"/>
 <result pre="This study successfully constructed the pneumonia murine model using IAV." exact="Olaparib" post="decreased IAV-induced mortality in mice, lung injury, and cytokine"/>
 <result pre="is available to authorized users. Keywords Influenza A virus PARP" exact="Olaparib" post="Pneumonia Cytokines Introduction Influenza is an acute infectious disease"/>
 <result pre="by elastase and LPS [9, 12]. Yet the role of" exact="olaparib" post="on IAV-induced lung injury has rarely been reported. This"/>
 <result pre="study aimed to explore the effects of PARP inhibition by" exact="olaparib" post="on IAV infection. Methods and materials Animals Specific-pathogen-free 8-"/>
 <result pre="to previously described [13]. Briefly, ketamine (50Â mg/kg weight) and" exact="pentobarbital" post="(30Â mg/kg weight) were intraperitoneally injected to induce the"/>
 <result pre="virusâ€‰+â€‰normal saline), and the IAVâ€‰+â€‰Ola group (H1N1 virusâ€‰+â€‰10Â mg/kg olaparib)." exact="Olaparib" post="(Selleck Chemicals, Houston, TX, USA) at different doses was"/>
 <result pre="0.75-mM hydrogen peroxide (80Â Î¼l), 2.9-mM TMB dissolved in 14.5%" exact="dimethyl sulfoxide" post="(110Â Î¼l), and 150-mM sodium phosphate buffer (pHÂ 5.4)"/>
 <result pre="test using the SPSS software (Chicago, IL, USA). pâ€‰ Results" exact="Olaparib" post="decreased IAV-induced mortality in mice This study aimed to"/>
 <result pre="IAV-induced mortality in mice This study aimed to investigate whether" exact="olaparib" post="(chemical structure in Fig.Â 1a) possessed protective effects against"/>
 <result pre="in the IAV-only group. To the expectations, mice in the" exact="olaparib" post="group showed higher survival rate compared with that in"/>
 <result pre="in the IAV group in a dose-dependent manner, indicating that" exact="olaparib" post="could powerfully protect against influenza virus challenge in mice."/>
 <result pre="side effects (Fig. S1). Also, the dose of 10Â mg/kg" exact="olaparib" post="was chosen for further investigation as a result of"/>
 <result pre="as a result of the highest survival rate among all" exact="olaparib" post="groups. Fig. 1 Effects of olaparib on influenza virus"/>
 <result pre="survival rate among all olaparib groups. Fig. 1 Effects of" exact="olaparib" post="on influenza virus challenge-induced mortality in mice. (a) Chemical"/>
 <result pre="15 consecutive days. Oseltamivir was used as positive control. Ola," exact="olaparib" post="group; IAV, influenza A virus-infected group. nâ€‰=â€‰20 in each"/>
 <result pre="influenza A virus-infected group. nâ€‰=â€‰20 in each group. *pâ€‰**pâ€‰ ***pâ€‰" exact="Olaparib" post="relieved IAV-induced lung injury in mice As olaparib treatment"/>
 <result pre="*pâ€‰**pâ€‰ ***pâ€‰ Olaparib relieved IAV-induced lung injury in mice As" exact="olaparib" post="treatment evidently reduced the virus-induced mortality, pathological changes were"/>
 <result pre="pathological changes were further explored to assess the influences of" exact="olaparib" post="on the lung injury severity. In comparison with the"/>
 <result pre="was significantly higher than that in the control group, and" exact="olaparib" post="treatment remarkably reduced the lung index, suggesting that olaparib"/>
 <result pre="and olaparib treatment remarkably reduced the lung index, suggesting that" exact="olaparib" post="could alleviate the pulmonary edema induced by IVA infection"/>
 <result pre="MPO levels compared with that in the control group, whereas" exact="olaparib" post="evidently reduced MPO levels, illustrating that olaparib reduced leucocyte"/>
 <result pre="control group, whereas olaparib evidently reduced MPO levels, illustrating that" exact="olaparib" post="reduced leucocyte infiltration to the lungs of IAV mice."/>
 <result pre="might lead to the breathing difficulty in infected mice. And" exact="olaparib" post="treatment attenuated the pathological abnormalities in IAV lungs. Lung"/>
 <result pre="abnormalities in IAV lungs. Lung histopathological grading numerically pointed that" exact="olaparib" post="rectified the lung injury caused by IAV infection (Fig."/>
 <result pre="caused by IAV infection (Fig. 2e). Fig. 2 Effects of" exact="olaparib" post="on influenza virus challenge-induced lung injuries at day 6"/>
 <result pre="group). Data were presented as meanâ€‰Â±â€‰SD. ##pâ€‰ ###pâ€‰ *pâ€‰ **pâ€‰" exact="Olaparib" post="reduced IAV-induced cytokine release in murine lungs Virus-infected pneumonia"/>
 <result pre="inflammatory cytokines in lung homogenate was detected to investigate whether" exact="olaparib" post="could influence the release of inflammatory cytokines in lung"/>
 <result pre="cytokine, IL-10, was remarkably descended in the IAV group, while" exact="olaparib" post="treatment obviously rectified the abnormal release of the above"/>
 <result pre="the abnormal release of the above inflammatory cytokines, meaning that" exact="olaparib" post="might possess anti-inflammatory effect in murine lung tissue under"/>
 <result pre="lung tissue under the IAV context. Fig. 3 Effects of" exact="olaparib" post="on influenza virus challenge-induced cytokine release in lung homogenate"/>
 <result pre="ELISA. Data were presented as meanâ€‰Â±â€‰SD. ##pâ€‰ ###pâ€‰ *pâ€‰ **pâ€‰" exact="Olaparib" post="reduced IAV-induced cytokine release in murine BALF The detection"/>
 <result pre="IAV group compared with those in the control group, while" exact="olaparib" post="treatment significantly reduced the abnormal increased levels of the"/>
 <result pre="obtained from lung tissue (Fig.Â 4a-h). Fig. 4 Effects of" exact="olaparib" post="on influenza virus challenge-induced cytokine and chemokine release in"/>
 <result pre="by ELISA. Data were presented as meanâ€‰Â±â€‰SD. ###pâ€‰ *pâ€‰**pâ€‰ ***pâ€‰" exact="Olaparib" post="decreased PARylated protein content and p65, IÎºBÎ± phosphorylation in"/>
 <result pre="tissues To explore the mechanisms underlying the protective effect of" exact="olaparib" post="against IAV-induced injury to murine lungs, western blot was"/>
 <result pre="homogenate samples compared with the control group, while PARP inhibitor" exact="olaparib" post="significantly reduced the PARylated protein content in IAV-infected samples"/>
 <result pre="c). NF-ÎºB genes are reported to be the targets of" exact="olaparib" post="in the context of LPS stimulation to the lungs"/>
 <result pre="lung homogenates compared with those of the control group, while" exact="olaparib" post="obviously decreased the abnormal increase of the two proteins,"/>
 <result pre="decreased the abnormal increase of the two proteins, suggesting that" exact="olaparib" post="inhibits the activation of NF-ÎºB signaling pathway in the"/>
 <result pre="IkBa among different groups (Fig. 5b). Fig. 5 Effects of" exact="olaparib" post="on influenza virus challenge-induced PARylated protein content and p65,"/>
 <result pre="study investigated for the first time the possible role of" exact="olaparib" post="on IAV infection in a murine model and found"/>
 <result pre="infection in a murine model and found that PARP-1 inhibitor" exact="olaparib" post="remarkably relieved IAV-induced lung injury and lung inflammation possibly"/>
 <result pre="injury induced by ALI [34]. As a potent PARP inhibitor," exact="olaparib" post="has already been approved to be used in cancer"/>
 <result pre="used in cancer patients for clinical trials with acceptable toxicity." exact="Olaparib" post="downregulates NF-ÎºB-related genes including TNF-Î± and IL-1Î², decreases neutrophil,"/>
 <result pre="edema of LPS-stimulated murine lungs [12]. Our study found that" exact="olaparib" post="possesses protective effects against IAV-induced lung inflammation, suggesting that"/>
 <result pre="damages to patients. Our study explored the protective effects of" exact="olaparib" post="in experimental virus-induced pneumonia, suggesting its possible application in"/>
 <result pre="We did not perform toxicity analysis about the influence of" exact="olaparib" post="on normal physiology of mice. The relationship between PARP-1/NF-ÎºB"/>
 <result pre="present study successfully constructed the pneumonia murine model using IAV." exact="Olaparib" post="decreased IAV-induced mortality in mice, lung injury, and cytokine"/>
 <result pre="PARP-1/NF-ÎºB axis. This study indicates the non-specific anti-inflammatory effect of" exact="olaparib" post="in lung disorders and would shine light on the"/>
 <result pre="of NF-kappaB and p38 MAPK pathwayJ Pharm Anal202010213014610.1016/j.jpha.2019.09.00532373385 12.KapoorKSinglaESahuBNauraASPARP inhibitor," exact="olaparib" post="ameliorates acute lung and kidney injury upon intratracheal administration"/>
 <result pre="Biochem20154001â€&quot;215316210.1007/s11010-014-2271-425404465 13.HatayamaKNosakaNYamadaMYashiroMFujiiYTsukaharaHLiuKNishiboriMMatsukawaAMorishimaTCombined effect of anti-high-mobility group box-1 monoclonal antibody and" exact="peramivir" post="against influenza A virus-induced pneumonia in miceJ Med Virol201991336136910.1002/jmv.2533030281823"/>
 <result pre="myeloperoxidase activity in biological samplesPLoS One201387e6797610.1371/journal.pone.006797623861842 17.LiYCPengSZChenHMZhangFXXuPPXieJHHeJJChenJNLaiXPSuZROral administration of patchouli" exact="alcohol" post="isolated from Pogostemonis Herba augments protection against influenza viral"/>
</results>
